Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 120

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers

Dearth, Lawrence R., Qian, Hua, Wang, Ting, Baroni, Timothy E., Zeng, Jue, Chen, Stephanie W., Yi, Sun Young, Brachmann, Rainer K.·2007·Carcinogenesis
DOI 10.1093/carcin/bgl132
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/carcin/bgl132

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 52

  1. Prives, 1999, The p53 pathway, J. Pathol., 187, 112, 10.1002/(SICI)1096-9896(199901)187:1<112::AID-PATH250>3.0.CO;2-3 · doi:10.1002/(sici)1096-9896(199901)187:1<112::aid-path250>3.0.co;2-3
  2. Corcoran, 2004, The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest, Cancer. Biol. Ther., 3, 721, 10.4161/cbt.3.8.1068 · DOI
  3. Ho, 2003, Transcriptional repression mediated by the p53 tumour suppressor, Cell. Death Differ., 10, 404, 10.1038/sj.cdd.4401191 · DOI · Paper page
  4. Erster, 2005, Stress-induced p53 runs a transcription-independent death program, Biochem. Biophys. Res. Commun., 331, 843, 10.1016/j.bbrc.2005.03.187 · DOI
  5. Hamroun, 2006, The UMD TP53 database and website: update and revisions, Hum. Mutat., 27, 14, 10.1002/humu.20269 · DOI · Paper page
  6. Bullock, 2001, Rescuing the function of mutant p53, Nat. Rev. Cancer, 1, 68, 10.1038/35094077 · DOI · Paper page
  7. Sigal, 2000, Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome, Cancer Res., 60, 6788
  8. Blagosklonny, 2000, p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect, FASEB J., 14, 1901, 10.1096/fj.99-1078rev · DOI · Paper page
  9. Greenblatt, 1994, Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis, Cancer Res., 54, 4855
  10. Ko, 1996, p53: puzzle and paradigm, Genes Dev., 10, 1054, 10.1101/gad.10.9.1054 · DOI · Paper page
  11. Campomenosi, 2001, p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements, Oncogene, 20, 3573, 10.1038/sj.onc.1204468 · DOI
  12. Di Como, 1998, Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay, Oncogene, 16, 2527, 10.1038/sj.onc.1202041 · DOI · Paper page
  13. Flaman, 1998, Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast, Oncogene, 16, 1369, 10.1038/sj.onc.1201889 · DOI
  14. Friedlander, 1996, Regulation of mutant p53 temperature-sensitive DNA binding, J. Biol. Chem., 271, 25468, 10.1074/jbc.271.41.25468 · DOI
  15. Ludwig, 1996, Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function, Mol. Cell. Biol., 16, 4952, 10.1128/MCB.16.9.4952 · DOI · Paper page
  16. Rowan, 1996, Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant, EMBO J, 15, 827, 10.1002/j.1460-2075.1996.tb00418.x · DOI · Paper page
  17. Milner, 1991, Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation, Cell, 65, 765, 10.1016/0092-8674(91)90384-B · DOI · Paper page
  18. Brachmann, 1996, Dominant-negative p53 mutations selected in yeast hit cancer hot spots, Proc. Natl Acad. Sci. USA, 93, 4091, 10.1073/pnas.93.9.4091 · DOI
  19. Aurelio, 2000, p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines, Mol. Cell. Biol., 20, 770, 10.1128/MCB.20.3.770-778.2000 · DOI
  20. de Vries, 2002, Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function, Proc. Natl Acad. Sci. USA, 99, 2948, 10.1073/pnas.052713099 · DOI · Paper page
  21. Lang, 2004, Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome, Cell, 119, 861, 10.1016/j.cell.2004.11.006 · DOI · Paper page
  22. Scharer, 1992, Mammalian p53 can function as a transcription factor in yeast, Nucleic Acids Res., 20, 1539, 10.1093/nar/20.7.1539 · DOI · Paper page
  23. Ishioka, 1993, Screening patients for heterozygous p53 mutations using a functional assay in yeast, Nat. Genet., 5, 124, 10.1038/ng1093-124 · DOI · Paper page
  24. Kato, 2003, Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis, Proc. Natl Acad. Sci. USA, 100, 8424, 10.1073/pnas.1431692100 · DOI · Paper page
  25. Resnick, 2003, Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity, Proc. Natl Acad. Sci. USA, 100, 9934, 10.1073/pnas.1633803100 · DOI · Paper page
  26. Robert, 2000, High frequency in esophageal cancers of p53 alterations inactivating the regulation of genes involved in cell cycle and apoptosis, Carcinogenesis, 21, 563, 10.1093/carcin/21.4.563 · DOI
  27. Inga, 1997, Simple identification of dominant p53 mutants by a yeast functional assay, Carcinogenesis, 18, 2019, 10.1093/carcin/18.10.2019 · DOI
  28. Marutani, 1999, Dominant-negative mutations of the tumor suppressor p53 relating to early onset of glioblastoma multiforme, Cancer Res., 59, 4765
  29. Monti, 2002, Tumour p53 mutations exhibit promoter selective dominance over wild type p53, Oncogene, 21, 1641, 10.1038/sj.onc.1205250 · DOI
  30. Brachmann, 1998, Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations, EMBO J., 17, 1847, 10.1093/emboj/17.7.1847 · DOI · Paper page
  31. Baroni, 2004, A global suppressor motif for p53 cancer mutants, Proc. Natl Acad. Sci. USA, 101, 4930, 10.1073/pnas.0401162101 · DOI
  32. Vidal, 1996, Reverse two-hybrid and one-hybrid systems to detect dissociation of protein–protein and DNA–protein interactions, Proc. Natl Acad. Sci. USA, 93, 10315, 10.1073/pnas.93.19.10315 · DOI · Paper page
  33. Qian, 2002, Groups of p53 target genes involved in specific p53 downstream effects cluster into different classes of DNA binding sites, Oncogene, 21, 7901, 10.1038/sj.onc.1205974 · DOI
  34. Kern, 1992, Oncogenic forms of p53 inhibit p53-regulated gene expression, Science, 256, 827, 10.1126/science.1589764 · DOI · Paper page
  35. Baker, 1990, Suppression of human colorectal carcinoma cell growth by wild-type p53, Science, 249, 912, 10.1126/science.2144057 · DOI · Paper page
  36. Dearth, 2003, Posttranscriptional and posttranslational regulation of C/EBP delta in G0 growth-arrested mammary epithelial cells, J. Biol. Chem., 278, 11246, 10.1074/jbc.M207930200 · DOI
  37. Bond, 2004, A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans, Cell, 119, 591, 10.1016/j.cell.2004.11.022 · DOI · Paper page
  38. Bougeard, 2006, Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome, J. Med. Genet., 43, 531, 10.1136/jmg.2005.037952 · DOI · Paper page
  39. Soussi, 2005, Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations, Hum. Mutat., 25, 6, 10.1002/humu.20114 · DOI
  40. Olivier, 2003, Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype, Cancer Res., 63, 6643
  41. Varley, 2003, Germline TP53 mutations and Li-Fraumeni syndrome, Hum. Mutat., 21, 313, 10.1002/humu.10185 · DOI · Paper page
  42. Trkova, 2003, A Li-Fraumeni syndrome family with retained heterozygosity for a germline TP53 mutation in two tumors, Cancer Genet. Cytogenet., 145, 60, 10.1016/S0165-4608(03)00031-1 · DOI
  43. Varley, 1997, A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene, Oncogene, 14, 865, 10.1038/sj.onc.1201041 · DOI
  44. Huang, 2000, High frequency allelic loss on chromosome 17p13.3-p11.1 in esophageal squamous cell carcinomas from a high incidence area in northern China, Carcinogenesis, 21, 2019, 10.1093/carcin/21.11.2019 · DOI
  45. Guan, 2003, Evidence for another tumor suppressor gene at 17p13.3 distal to TP53 in hepatocellular carcinoma, Cancer Genet. Cytogenet., 140, 45, 10.1016/S0165-4608(02)00654-4 · DOI
  46. Konishi, 1998, Detailed deletion mapping suggests the involvement of a tumor suppressor gene at 17p13.3, distal to p53, in the pathogenesis of lung cancers, Oncogene, 17, 2095, 10.1038/sj.onc.1202128 · doi:10.1038/sj.onc.1202128
  47. Soussi, 2003, p53 mutations and resistance to chemotherapy: a stab in the back for p73, Cancer Cell, 3, 303, 10.1016/S1535-6108(03)00081-3 · DOI
  48. Moll, 2004, p63 and p73: roles in development and tumor formation, Mol. Cancer Res., 2, 371, 10.1158/1541-7786.371.2.7 · DOI · Paper page
  49. Marin, 2000, A common polymorphism acts as an intragenic modifier of mutant p53 behaviour, Nat. Genet., 25, 47, 10.1038/75586 · DOI · Paper page
  50. Bergamaschi, 2003, p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis, Cancer Cell, 3, 387, 10.1016/S1535-6108(03)00079-5 · DOI · Paper page
  51. Russo, 2005, The TP53 Colorectal Cancer International Collaborative Study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment, J. Clin. Oncol., 23, 7518, 10.1200/JCO.2005.00.471 · DOI · Paper page
  52. Olivier, 2006, The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer, Clin. Cancer Res., 12, 1157, 10.1158/1078-0432.CCR-05-1029 · DOI · Paper page

Cited by

See all 120

Metadata

Authors
Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K.
Venue
Carcinogenesis
Publisher
Oxford University Press (OUP)
Published
2007-02
Volume
28
Issue
2
Pages
289-298
ISSN
  • 1460-2180
  • 0143-3334
DOI
10.1093/carcin/bgl132
Cited by
120
References
8
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. https://app.cochat.ai/papers/10.1093/carcin/bgl132
The paper
Dearth, L. R., Qian, H., Wang, T., Baroni, T. E., Zeng, J., Chen, S. W., Yi, S. Y., & Brachmann, R. K. (2007). Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers. Carcinogenesis. https://doi.org/10.1093/carcin/bgl132

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.